Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
life sciences
national blog main
boulder/denver blog main
boulder/denver top stories
crispr
detroit blog main
detroit top stories
editas medicine
gene editing
glaxosmithkline
katrine bosley
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
translate bio
wisconsin blog main
wisconsin top stories
abbvie
advaxis
adverum biotechnologies
aimmune therapeutics
albert bourla
alder biopharmaceuticals
alexander hardy
allergan
What
ceo
3
×
crispr
3
×
bio
editas
katrine
medicine
roundup
acquisitions
albert
allergan
big
biggest
blessing
bosley
bosley's
bosley’s
bourla
bridge
bucks
cas
check
clinical
company
crime
cusp
depart
departure
drug
editing
exit
experimental
future
gene
guiding
humans
imports
maker
maps
measured
million
Language
unknown
Current search:
biotech
×
ceo
×
crispr
×
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial